In May, Merck & Co., Inc. entered into a definitive agreement to acquire Rosetta Inpharmatics, Inc. Under the agreement each share of Rosetta's stock would be converted into 0.2352 shares of Merck stock, representing a value of $18 per share. Rosetta Inpharmatics, Inc. operates in the field of informational genomics. Its solutions include the Rosetta Resolver Expression Data Analysis System, FlexJet DNA microarray technology, and coherent data sets of information. Its Rosetta Resolver Expression Data Analysis System is an enterprise-level software product enabling organizations to assemble, store, and analyze gene expression data from multiple experiments. The FlexJet DNA microarrays solution allows the company to monitor small changes in the expression levels of genes. The company builds coherent sets of data generated from DNA microarrays that represent the responses of cells to different genetic and disease states and to drug treatments. As of July 19, 2001, Rosetta Inpharmatics, Inc is a subsidiary of Merck & Co., Inc.